Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32


Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness.

Segerberg F, Lundtoft C, Reid S, Hjorton K, Leonard D, Nordmark G, Carlsten M, Hagberg N.

Front Immunol. 2019 Sep 11;10:2164. doi: 10.3389/fimmu.2019.02164. eCollection 2019.


Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4R334X.

Levy E, Reger R, Segerberg F, Lambert M, Leijonhufvud C, Baumer Y, Carlsten M, Childs R.

Front Immunol. 2019 Jun 5;10:1262. doi: 10.3389/fimmu.2019.01262. eCollection 2019.


Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.

Daly J, Carlsten M, O'Dwyer M.

Front Immunol. 2019 May 9;10:1047. doi: 10.3389/fimmu.2019.01047. eCollection 2019. Review.


The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994-2016.

Carlsten M, Jädersten M, Hellström A, Littmann K, Melén CM, Junlén HR, Sonnevi K, Ljungman P, Björkstrand B, Wahlin BE.

Exp Hematol Oncol. 2019 Mar 18;8:7. doi: 10.1186/s40164-019-0131-3. eCollection 2019.


Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5.

Carlsten M, Namazi A, Reger R, Levy E, Berg M, St Hilaire C, Childs RW.

Oncoimmunology. 2018 Nov 2;8(2):e1534664. doi: 10.1080/2162402X.2018.1534664. eCollection 2019.


Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of follow-up.

Hagström H, Andreasson A, Carlsson AC, Jerkeman M, Carlsten M.

PLoS One. 2018 Aug 23;13(8):e0202651. doi: 10.1371/journal.pone.0202651. eCollection 2018.


Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.

Björklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, Cooley S, Miller JS, Klimkowska M, Schaffer M, Watz E, Wikström K, Blomberg P, Wahlin BE, Palma M, Hansson L, Ljungman P, Hellström-Lindberg E, Ljunggren HG, Malmberg KJ.

Clin Cancer Res. 2018 Apr 15;24(8):1834-1844. doi: 10.1158/1078-0432.CCR-17-3196. Epub 2018 Feb 14.


Natural killer cell-mediated immunosurveillance of human cancer.

Malmberg KJ, Carlsten M, Björklund A, Sohlberg E, Bryceson YT, Ljunggren HG.

Semin Immunol. 2017 Jun;31:20-29. doi: 10.1016/j.smim.2017.08.002. Epub 2017 Sep 6. Review.


Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma.

Carlsten M, Korde N, Kotecha R, Reger R, Bor S, Kazandjian D, Landgren O, Childs RW.

Clin Cancer Res. 2016 Nov 1;22(21):5211-5222. Epub 2016 Jun 15.


mRNA Transfection to Improve NK Cell Homing to Tumors.

Levy ER, Carlsten M, Childs RW.

Methods Mol Biol. 2016;1441:231-40. doi: 10.1007/978-1-4939-3684-7_19.


Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19.

Carlsten M, Levy E, Karambelkar A, Li L, Reger R, Berg M, Peshwa MV, Childs RW.

Front Immunol. 2016 Mar 22;7:105. doi: 10.3389/fimmu.2016.00105. eCollection 2016.


The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies.

Dosani T, Carlsten M, Maric I, Landgren O.

Blood Cancer J. 2015 Jul 3;5:e321. doi: 10.1038/bcj.2015.49. No abstract available.


Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.

Carlsten M, Childs RW.

Front Immunol. 2015 Jun 10;6:266. doi: 10.3389/fimmu.2015.00266. eCollection 2015. Review.


Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Childs RW, Carlsten M.

Nat Rev Drug Discov. 2015 Jul;14(7):487-98. doi: 10.1038/nrd4506. Epub 2015 May 22. Review.


The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.

Dosani T, Carlsten M, Maric I, Landgren O.

Blood Cancer J. 2015 Apr 17;5:e306. doi: 10.1038/bcj.2015.32. Review. Erratum in: Blood Cancer J. 2015;5:e321.


Coordinated expression of DNAM-1 and LFA-1 in educated NK cells.

Enqvist M, Ask EH, Forslund E, Carlsten M, Abrahamsen G, Béziat V, Andersson S, Schaffer M, Spurkland A, Bryceson Y, Önfelt B, Malmberg KJ.

J Immunol. 2015 May 1;194(9):4518-27. doi: 10.4049/jimmunol.1401972. Epub 2015 Mar 30.


Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.

Ito S, Bollard CM, Carlsten M, Melenhorst JJ, Biancotto A, Wang E, Chen J, Kotliarov Y, Cheung F, Xie Z, Marincola F, Tanimoto K, Battiwalla M, Olnes MJ, Perl S, Schum P, Hughes TE, Keyvanfar K, Hensel N, Muranski P, Young NS, Barrett AJ.

Mol Ther. 2014 Jul;22(7):1388-1395. doi: 10.1038/mt.2014.50. Epub 2014 Apr 1.


A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.

Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O.

Haematologica. 2014 Jun;99(6):e81-3. doi: 10.3324/haematol.2013.103085. Epub 2014 Mar 21. No abstract available.


Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.

Wennerberg E, Sarhan D, Carlsten M, Kaminskyy VO, D'Arcy P, Zhivotovsky B, Childs R, Lundqvist A.

Int J Cancer. 2013 Oct 1;133(7):1643-52. doi: 10.1002/ijc.28163. Epub 2013 Apr 11.


Selenite induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/NKG2A-positive NK cells.

Enqvist M, Nilsonne G, Hammarfjord O, Wallin RP, Björkström NK, Björnstedt M, Hjerpe A, Ljunggren HG, Dobra K, Malmberg KJ, Carlsten M.

J Immunol. 2011 Oct 1;187(7):3546-54. doi: 10.4049/jimmunol.1100610. Epub 2011 Sep 2.


Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.

Carlsten M, Baumann BC, Simonsson M, Jädersten M, Forsblom AM, Hammarstedt C, Bryceson YT, Ljunggren HG, Hellström-Lindberg E, Malmberg KJ.

Leukemia. 2010 Sep;24(9):1607-16. doi: 10.1038/leu.2010.149. Epub 2010 Jul 8.


Regulation of interleukin-4 signaling by extracellular reduction of intramolecular disulfides.

Curbo S, Gaudin R, Carlsten M, Malmberg KJ, Troye-Blomberg M, Ahlborg N, Karlsson A, Johansson M, Lundberg M.

Biochem Biophys Res Commun. 2009 Dec 25;390(4):1272-7. doi: 10.1016/j.bbrc.2009.10.134. Epub 2009 Oct 28.


Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells.

Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HG, Kiessling R, Malmberg KJ.

J Immunol. 2009 Oct 15;183(8):4921-30. doi: 10.4049/jimmunol.0901226.


Natural killer cell-mediated lysis of freshly isolated human tumor cells.

Carlsten M, Malmberg KJ, Ljunggren HG.

Int J Cancer. 2009 Feb 15;124(4):757-62. doi: 10.1002/ijc.24082. Review.


Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype.

Fauriat C, Andersson S, Björklund AT, Carlsten M, Schaffer M, Björkström NK, Baumann BC, Michaëlsson J, Ljunggren HG, Malmberg KJ.

J Immunol. 2008 Nov 1;181(9):6010-9.


NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy.

Malmberg KJ, Bryceson YT, Carlsten M, Andersson S, Björklund A, Björkström NK, Baumann BC, Fauriat C, Alici E, Dilber MS, Ljunggren HG.

Cancer Immunol Immunother. 2008 Oct;57(10):1541-52. doi: 10.1007/s00262-008-0492-7. Epub 2008 Mar 4. Review.


DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells.

Carlsten M, Björkström NK, Norell H, Bryceson Y, van Hall T, Baumann BC, Hanson M, Schedvins K, Kiessling R, Ljunggren HG, Malmberg KJ.

Cancer Res. 2007 Feb 1;67(3):1317-25.


A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients.

Hanson MG, Ozenci V, Carlsten MC, Glimelius BL, Frödin JE, Masucci G, Malmberg KJ, Kiessling RV.

Cancer Immunol Immunother. 2007 Jul;56(7):973-84. Epub 2006 Dec 2.


Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity.

Norell H, Carlsten M, Ohlum T, Malmberg KJ, Masucci G, Schedvins K, Altermann W, Handke D, Atkins D, Seliger B, Kiessling R.

Cancer Res. 2006 Jun 15;66(12):6387-94.


IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.

Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, Rabbani H, Moretta A, Söderström K, Levitskaya J, Kiessling R.

J Clin Invest. 2002 Nov;110(10):1515-23.

Supplemental Content

Loading ...
Support Center